CN110404001A - 一种具有增强免疫力、改善记忆及抗氧化功能的组合物及其应用 - Google Patents
一种具有增强免疫力、改善记忆及抗氧化功能的组合物及其应用 Download PDFInfo
- Publication number
- CN110404001A CN110404001A CN201910656409.1A CN201910656409A CN110404001A CN 110404001 A CN110404001 A CN 110404001A CN 201910656409 A CN201910656409 A CN 201910656409A CN 110404001 A CN110404001 A CN 110404001A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- ginseng
- jujube
- donkey
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000006870 function Effects 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 230000036039 immunity Effects 0.000 title claims abstract description 16
- 230000003064 anti-oxidating effect Effects 0.000 title claims abstract description 15
- 108010010803 Gelatin Proteins 0.000 claims abstract description 20
- 229920000159 gelatin Polymers 0.000 claims abstract description 20
- 239000008273 gelatin Substances 0.000 claims abstract description 20
- 235000019322 gelatine Nutrition 0.000 claims abstract description 20
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 20
- 108010052008 colla corii asini Proteins 0.000 claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 16
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 14
- 235000020234 walnut Nutrition 0.000 claims abstract description 14
- 235000012907 honey Nutrition 0.000 claims abstract description 11
- 235000019991 rice wine Nutrition 0.000 claims abstract description 11
- 239000011435 rock Substances 0.000 claims abstract description 11
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 36
- 241000005787 Cistanche Species 0.000 claims description 24
- 244000197580 Poria cocos Species 0.000 claims description 22
- 235000008599 Poria cocos Nutrition 0.000 claims description 22
- 241000208340 Araliaceae Species 0.000 claims description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 20
- 235000008434 ginseng Nutrition 0.000 claims description 20
- 229940026510 theanine Drugs 0.000 claims description 17
- 241001247821 Ziziphus Species 0.000 claims description 14
- 241000758789 Juglans Species 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 241001251949 Xanthium sibiricum Species 0.000 claims 2
- 244000126002 Ziziphus vulgaris Species 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 4
- 230000003712 anti-aging effect Effects 0.000 abstract description 2
- 230000013016 learning Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 240000007049 Juglans regia Species 0.000 abstract 1
- 240000008866 Ziziphus nummularia Species 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 42
- 230000000694 effects Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 230000000242 pagocytic effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000002949 hemolytic effect Effects 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000003024 peritoneal macrophage Anatomy 0.000 description 5
- 230000007815 allergy Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000955 splenic vein Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001149422 Ganoderma applanatum Species 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000308150 Orobanchaceae Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Insects & Arthropods (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Animal Husbandry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
Abstract
本发明提供了一种具有增强免疫力、改善记忆、抗氧化功能的组合物,该组合物包括阿胶20~30份、核桃仁4~10份、黑芝麻4~10份、枸杞子3~8份、大枣4~10份、冰糖1~5份、黄酒30~60份、蜂蜜1~5份。通过实验表明根据该组合物所制得的阿胶糕具有增强免疫力、改善记忆、抗氧化的功能。坚持服用能够增强体质,改善记忆力、提高学习能力,对延缓衰老很有裨益。
Description
技术领域
本发明涉及药品、食品或保健品领域,具体涉及一种具有增强免疫力、改善记忆、抗氧化功能的组合物及其制备方法和应用。
背景技术
阿胶糕属于药食同源产品,可采用阿胶配以黑芝麻、新疆大枣等药食两用的天然原料精制而成,其具有补血补气、固本培元之效。
目前市面上有一些阿胶糕,其主要原料为阿胶,常见添加黑芝麻、大枣等原料,根据添加的原辅料的不同可能会产生不同的功效,但是现有技术中的阿胶糕,都没有把功能划分得很清楚,也没有针对性的人群,所以难以更好地发挥阿胶糕的功效。
发明内容
本发明的目的在于提供一种具有增强免疫力、改善记忆及抗氧化功能的组合物,通过添加一定的辅料或添加剂得到一种具有保健功能的阿胶糕。
具体地,本发明提供一种具有增强免疫力、改善记忆、抗氧化功能的组合物,其特征在于,以重量计,所述组合物包括阿胶20~30份、核桃仁4~10份、黑芝麻4~10份、枸杞子3~8份、大枣4~10份、冰糖1~5份、黄酒30~60份、蜂蜜1~5份。本发明的组合物可以直接研磨成粉,也可以是经过本领域常规手段制得的提取物等。本发明组合物中使用的原材料也可以以直接研磨成粉、提取物、或者其它加工形态的方式使用。
进一步地,所述组合物包括:阿胶25~30份、核桃仁4~8份、黑芝麻4~8份、枸杞子5~8份、大枣4~8份、冰糖1~2份、黄酒40~50份、蜂蜜1~2份。
优选地,所述组合物包括:阿胶25份、核桃仁6份、黑芝麻7份、枸杞子7份、大枣5份、冰糖1份、黄酒40份、蜂蜜1份。
进一步地,前述组合物还包括:肉苁蓉10~15份、茯苓1~5份、人参1~2份、茶氨酸0.4~2份。
进一步地,前述组合物还包括:肉苁蓉10~15份、茯苓2~4份、人参1~2份、茶氨酸0.4~1份。
优选地,前述组合物还包括:肉苁蓉15份、茯苓3份、人参2份、茶氨酸0.6份、
本发明还提出了一种如前任一所述的组合物在制备具有增强免疫力、改善记忆或抗氧化功能的产品中的应用,该产品可以选自药物、保健品或食品。
本发明还提出了一种如前任一所述的组合物的产品,该产品可以是口服剂型、注射剂型或外用剂型。
进一步地,前述产品中还包括药品或食品上可接受的辅料,包括但不限于乳糖、蔗糖、甘露醇或山梨醇、甜菊糖苷、明胶、黄芪胶、黄原胶、卡拉胶、魔芋胶。
本发明还提出了一种如前述产品的制备方法,当该产品选自阿胶糕时,制备方法包括:
(1)肉苁蓉洗净,切片,干燥后打粉备用;茯苓、人参打粉备用;
(2)核桃仁、黑芝麻分别炒熟备用;大枣切块备用;
(3)将阿胶、冰糖、蜂蜜按配方比例放入黄酒中,加热至溶解;继续加热熬胶,同时搅拌至微粘稠状;
(4)按配方比例加入肉苁蓉粉、茯苓粉、人参粉、大枣、核桃仁、枸杞子、黑芝麻、茶氨酸混合,搅拌均匀,隔水蒸煮,冷却,切块。
本发明所使用的部分材料功效如下:
阿胶,为马科动物驴的干燥皮或鲜皮经煎煮、浓缩制成的固体胶,与人参、鹿茸并称为“滋补三宝”,始载于《神农本草经》,列为上品,陶弘景曰:“出东阿,故名阿胶”。阿胶味甘、性平,归肺、肝、肾经。具有补血滋阴、润燥、止血之功效,被历代医家尊称为补血“圣药”。主治血虚萎黄,眩晕心悸,肌痿无力,心烦不眠,虚风内动,肺燥咳嗽,痨咳咯血,吐血尿血,便血崩漏,现代医学证明:阿胶具有强大的补血作用和抗休克作用,用于补血;止血;滋阴;润燥等,尤其适合体虚者调养身体。
肉苁蓉,为列当科植物肉苁蓉的带鳞片的干燥肉质茎,又名苁蓉、大芸、金笋、地精。始载于《神农本草经》,列为上品,其后古典《本草经疏》、《本草汇言》、《月华子本草》等多有记载。李时珍曰:“此物补而不峻,故有从容之兮”。肉苁蓉味甘、咸,性温,具有补肾阳、益精血、润肠通便的功能,在我国已有两千多年的使用历史。中医认为:肉苁蓉补肾阳;益精血;润肠道;主白浊;尿频余沥;腰痛脚弱;耳鸣目花;月经衍期;宫寒不孕;肠燥便秘。
茯苓,又称玉灵、茯灵、万灵桂、茯菟,是拟层孔菌科真菌茯苓的干燥菌核。茯苓性甘、淡,平;归心、肺、脾、肾经。具有利水渗湿,健脾,宁心之功效;主治水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠。茯苓宁心安神,败毒抗癌,药性平和,利湿而不伤正气,适量服食可作为春夏潮湿季节的调养佳品。
人参,别称黄参、地精、神草、百草之王,为五加科植物人参Panax ginsengC.A.Mey.的干燥根和根茎。;性甘、微苦,微温;归脾、肺、心、肾经;具有大补元气,复脉固脱,补脾益肺,生津养血,安神益智之功效;用于体虚欲脱,肢冷脉微,脾虚食少,肺虚喘咳,津伤口渴,内热消渴,气血亏虚,久病虚羸,惊悸失眠,阳痿宫冷。
茶氨酸(L-Theanine)是茶叶中特有的游离氨基酸,茶氨酸是谷氨酸γ-乙基酰胺,有甜味。在化学构造上与脑内活性物质谷酰胺、谷氨酸相似,是茶叶中生津润甜的主要成份。现代药理学研究表明,茶氨酸能抑制短暂脑缺血引起的神经细胞死亡,对神经细胞有保护作用。
本发明提供了具有增强免疫力、改善记忆及抗氧化功能的组合物,通过实验表明根据该组合物所制得的阿胶糕具有增强免疫力、改善记忆、抗氧化的功能。坚持服用能够增强体质,改善记忆力、提高学习能力,对延缓衰老很有裨益。
具体实施方式
如前所述,本发明旨在提供一种具有增强免疫力、改善记忆及抗氧化功能的组合物及其应用。以下将结合实验例的内容进行具体描述。
特别需要指出的是,针对本发明所做出的类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。
实施例1
本实施例中的阿胶糕包括阿胶25克、肉苁蓉15克、茯苓3克、人参2克、茶氨酸0.6克、核桃仁6克、黑芝麻7克、枸杞子7克、大枣5克、冰糖1克、黄酒40克、蜂蜜1克制备而成。
其制备方法如下:肉苁蓉清水洗净,切片,晾晒至完全晒干后打粉备用;茯苓、人参打粉备用;核桃仁、黑芝麻分别炒熟备用;大枣切块备用。将阿胶、冰糖、蜂蜜按配方比例放入黄酒中,小火加热至充分溶解;继续小火熬胶,同时搅拌以防止糊锅底,熬至微粘稠状。按配方比例加入肉苁蓉粉、茯苓粉、人参粉、大枣、核桃仁、枸杞子、黑芝麻、茶氨酸混合,搅拌均匀,隔水蒸煮至适宜粘稠度,冷却,切块,包装。
本实施例的阿胶糕在制备时,可以多剂一起制备,制备好后,可平均分好,真空包装,进行冷冻保存,需要服用时,取出一剂食用即可。
肉苁蓉茯苓阿胶糕的动物功能试验
1.材料和方法
1.1样品
样品a为本发明实施例1配方去除“肉苁蓉、茯苓、人参、茶氨酸”后同法制备的阿胶糕,10g/片。
样品b为本发明实施例1制备的阿胶糕,10g/片。
1.2实验动物
BALB/c小鼠,SPF级,18-22g,雄性,购自扬州大学比较医学中心,许可证号:SCXK(苏)2017-0007。动物分笼饲养,温度20-25℃,湿度40-70%,光照12/12h。
1.3剂量选择与给药
免疫力考察组:2个受试样品的小鼠给药剂量,按人体推荐剂量的10倍进行给药(以成人体重60kg,20g/人/天),即3.3g/kg;空白对照组给药相应重量的饲料,30天后按照《保健食品检验与评价技术规范》中功能学评价方法检测各项免疫指标。
抗氧化考察组:除空白对照组外,其余动物用D-半乳糖40mg/kg腹腔注射造模,注射量为0.1mL/10g,每日1次,连续造模6周,取血测MDA,按MDA水平分组。随机分为1个模型对照组和2个受试样品组,2个样品组经口分别给予样品a或b各3.3g/kg,模型对照组给予同重量的饲料,给药30天。在给受试样品的同时,模型对照组和样品组继续给予相同剂量D-半乳糖腹腔注射,实验结束处死动物取血。按照要求测MDA含量、蛋白质羰基含量、还原性谷胱甘肽(GSH)含量、SOD活力。
2.试验结果
2.1对小鼠体重的影响
小鼠给予样品30天后对小鼠体重的影响见表1。
表1对小鼠体重的影响
结果可见,在各试验组中,动物的初始体重和终末体重与对照组相比较均无显著性差异(P>0.05)。
2.2对小鼠脏器/体重比值的影响
小鼠给予样品30天后对脏器/体重比值的影响见表2。
表2脏器/体重比值的影响
由表2可见,小鼠脾脏/体重比值和胸腺/体重比值在样品a、b组与对照组间比较均无显著性差异(P>0.05),表明样品a、b对小鼠的脏器/体重比值无影响。
2.3对小鼠迟发型变态反应(DTH)的影响
小鼠给予样品30天后对迟发型变态反应(DTH)的影响见表3。
表3对小鼠迟发型变态反应(DTH)的影响
注:**与对照组比较有极显著性差异,P<0.01。
由表3可见,经口给予小鼠样品a、b各30天,经统计学处理,其足跖肿胀度(足跖增厚)在注射SRBC前后差值,样品b组与空白对照组间比较有极显著性差异(P<0.01);样品a组与空白对照组比较有增加,但效果不显著(P>0.05);结果表明样品b能显著增强小鼠的迟发型变态反应且效果比样品a好。
2.4对小鼠脾淋巴细胞转化的影响
给予小鼠样品30天后对小鼠脾淋巴细胞转化影响见表4。
表4对小鼠脾淋巴细胞转化的影响
注:*与对照组比较有显著性差异,P<0.05。
由表4可见,经口给予小鼠样品a、b各30天,经统计学处理,样品b组的小鼠脾淋巴细胞转化功能与空白对照组比较有显著性差异(P<0.05),结果表明样品b能显著增强小鼠脾淋巴细胞转化功能。
2.5对小鼠半数溶血值(HC50)的影响
给予小鼠样品30天后对小鼠半数溶血值(HC50)的影响见表5。
表5对小鼠半数溶血值(HC50)的影响
注:*与对照组比较有显著性差异,P<0.05;**与对照组比较有极显著性差异,P<0.01。
由表5可见,经口给予小鼠样品a、b各30天,样品b组的半数溶血值(HC50)与空白对照组比较有极显著性差异(P<0.01),样品a组的半数溶血值(HC50)与空白对照组比较有显著性差异(P<0.05),表明样品b能提高小鼠半数溶血值(HC50)且效果比样品a好。
2.6对小鼠碳廓清功能的影响
给予小鼠样品30天后对小鼠碳廓清功能的影响见表6。
表6对小鼠碳廓清功能的影响
注:*与对照组比较有显著性差异,P<0.05;**与对照组比较有极显著性差异,P<0.01。
由表6可见,经口给予小鼠样品a、b各30天,样品b组的吞噬指数(a)与空白对照组比较有极显著性差异(P<0.01),样品a组的吞噬指数(a)与空白对照组比较有显著性差异(P<0.05),表明样品b能增强小鼠碳廓清功能且效果比样品a好。
2.7对小鼠腹腔巨噬细胞吞噬鸡红细胞功能的影响
给予小鼠样品30天后对小鼠腹腔巨噬细胞吞噬鸡红细胞功能的影响见表7。
表7对小鼠腹腔巨噬细胞吞噬鸡红细胞功能的影响
注:*与对照组比较有显著性差异,P<0.05;**与对照组比较有极显著性差异,P<0.01。
由表7可见,经口给予小鼠样品a、b各30天后,经统计学处理,三组吞噬率进行方差齐性检验,方差不齐,进行变量变换式中P为吞噬率,用小数表示,为原始数据进行变量变换后且方差齐,进行的三组比较结果:样品b组的吞噬指数与空白对照组比较有极显著性差异(P<0.01);样品a组的吞噬指数与空白对照组比较有所提高,但无显著性差异(P>0.05);表明样品b组能增强小鼠腹腔巨噬细胞的吞噬功能且效果比样品a好。
小结:样品b能提高小鼠半数溶血值(HC50),显著增强小鼠的迟发型变态反应(DTH)、脾淋巴细胞转化功能、碳廓清功能、腹腔巨噬细胞的吞噬功能。根据“保健食品功能学评价程序和检验方法”中的判定标准,可以认定样品a组有一定的增强免疫力的作用,但样品b组效果比样品a好,添加“肉苁蓉、茯苓、人参、茶氨酸”使阿胶糕的增强免疫力功效更强。
2.8对小鼠抗氧化功能的影响
抗氧化考察组小鼠各指标含量见表8。
表8对小鼠抗氧化功能的影响
注:##与空白对照组比较有极显著性差异,P<0.01;*与模型对照组比较有显著性差异,P<0.05;**与模型对照组比较有极显著性差异,P<0.01。
从实验结果表8可知:与空白对照组相比,模型对照组各指标项均有极显著性差异(P<0.01),表明造模成功;与模型对照组相比,样品b组对MDA、蛋白质羰基均有一定的降低作用(P<0.05),对SOD含量有增高的作用(P<0.05),对GSH含量的提高具有极显著性(P<0.01);与模型对照组相比,样品a组对MDA有一定的降低作用(P<0.05),对蛋白质羰基降低作用不显著(P>0.05),对SOD含量有增高不显著(P>0.05),对GSH含量的提高有一定作用(P<0.05)。可见,样品a虽然有一定的抗氧化功能,但样品b组效果比样品a好,表明添加“肉苁蓉、茯苓、人参、茶氨酸”使阿胶糕的抗氧化功效更强。
本发明肉苁蓉茯苓阿胶糕的人体功能试验
1.样品
样品a为本发明实施例1配方去除“肉苁蓉、茯苓、人参、茶氨酸”后同法制备的阿胶糕,10g/片。
样品b为本发明实施例1制备的阿胶糕,10g/片。
2.受试对象
受试者未接受过类似测试,短期内未服用与受试功能有关的物品。服用受试样品前对受试者进行第一次记忆商测试后,按记忆商将受试者双盲法随机分为试食组与对照组,尽可能考虑文化水平、年龄等,进行均衡性检验。
试食方法:样品组分别服用受试品样品a或样品b,对照组服用安慰剂,每人每日推荐服用量为每日2次,每次10g,连续服用1个月。每组50人。
3.试验方法
试验方法按照《保健食品检验与评价技术规范》(2003年版)中辅助改善记忆功能的人体试食试验规程进行。
4.结果
4.1试食前受试者各测验项目得分见表9。
表9试食前受试者各测验项目得分
结果表明,试食前试食组与对照组比较,各测验项目得分和总分差异均无统计学意义(P>0.05)。
4.2试食后受试者各测验项目得分见表10。
表10试食后受试者各测验项目得分
注:*与对照组比较有显著性差异,P<0.05;**与对照组比较有极显著性差异,P<0.01。
结果表明,试食样品b组图片回忆、视觉再认、联想学习、理解记忆、触摸测验、理解记忆和背数测验项目得分均显著高于对照组(P<0.05,P<0.01),总分也显著高于对照组;试食样品a组仅有触摸测验、理解记忆和背数测验项目得分显著高于对照组(P<0.05),总分提高不明显(P>0.05)。
试食本品前后试食者一般情况等检查均未见明显异常,表明试食本品对人体未见不良影响。50例受试者试食本品1个月后,试食样品b组记忆商显著优于对照组,效果比样品a好。结果表明本品对人体具有改善记忆功效,添加“肉苁蓉、茯苓、人参、茶氨酸”使阿胶糕的改善记忆功效更强。
尽管这里参照本发明的解释性实施例对本发明进行了描述,但并不用以限制本发明,应该理解,本领域技术人员可以设计出很多其他的修改和实施方式,这些修改和实施方式将落在本申请公开的原则范围和精神之内。更具体地说,在本申请公开和权利要求的范围内,可以对主题组合布局的组成部件和/或布局进行多种变型和改进。除了对组成部件和/或布局进行的变型和改进外,对于本领域技术人员来说,本发明的功能和效果也将是明显的。
Claims (10)
1.一种具有增强免疫力、改善记忆、抗氧化功能的组合物,其特征在于,以重量计,所述组合物包括阿胶20~30份、核桃仁4~10份、黑芝麻4~10份、枸杞子3~8份、大枣4~10份、冰糖1~5份、黄酒30~60份、蜂蜜1~5份。
2.根据权利要求1所述的组合物,其特征在于,所述组合物包括:阿胶25~30份、核桃仁4~8份、黑芝麻4~8份、枸杞子5~8份、大枣4~8份、冰糖1~2份、黄酒40~50份、蜂蜜1~2份。
3.根据权利要求1所述的组合物,其特征在于,所述组合物包括:阿胶25份、核桃仁6份、黑芝麻7份、枸杞子7份、大枣5份、冰糖1份、黄酒40份、蜂蜜1份。
4.根据权利要求1所述的组合物,其特征在于,所述组合物还包括:肉苁蓉10~15份、茯苓1~5份、人参1~2份、茶氨酸0.4~2份。
5.根据权利要求2所述的组合物,其特征在于,所述组合物还包括:肉苁蓉10~15份、茯苓2~4份、人参1~2份、茶氨酸0.4~1份。
6.根据权利要求3所述的组合物,其特征在于,所述组合物还包括:肉苁蓉15份、茯苓3份、人参2份、茶氨酸0.6份。
7.权利要求1-6任一项所述的组合物在制备具有增强免疫力、改善记忆或抗氧化功能的产品中的应用。
8.一种含有权利要求1-6任一项所述组合物的产品。
9.如权利要求8所述的产品,其特征在于,还包括可接受的辅料。
10.如权利要求9所述产品的制备方法,其特征在于,所述产品选自阿胶糕,该制备方法包括:
(1)肉苁蓉洗净,切片,干燥后打粉备用;茯苓、人参打粉备用;
(2)核桃仁、黑芝麻分别炒熟备用;大枣切块备用;
(3)将阿胶、冰糖、蜂蜜按配方比例放入黄酒中,加热至溶解;继续加热熬胶,同时搅拌至微粘稠状;
(4)按配方比例加入肉苁蓉粉、茯苓粉、人参粉、大枣、核桃仁、枸杞子、黑芝麻、茶氨酸混合,搅拌均匀,隔水蒸煮,冷却,切块。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910656409.1A CN110404001A (zh) | 2019-07-19 | 2019-07-19 | 一种具有增强免疫力、改善记忆及抗氧化功能的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910656409.1A CN110404001A (zh) | 2019-07-19 | 2019-07-19 | 一种具有增强免疫力、改善记忆及抗氧化功能的组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110404001A true CN110404001A (zh) | 2019-11-05 |
Family
ID=68362032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910656409.1A Withdrawn CN110404001A (zh) | 2019-07-19 | 2019-07-19 | 一种具有增强免疫力、改善记忆及抗氧化功能的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110404001A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1781384A (zh) * | 2004-12-01 | 2006-06-07 | 山东东阿阿胶股份有限公司 | 阿胶膏及其制备方法 |
CN102335286A (zh) * | 2011-10-28 | 2012-02-01 | 尹留风 | 一种补肾安神食疗的中药组合物 |
CN102342497A (zh) * | 2010-07-30 | 2012-02-08 | 欧连 | 固元膏及加工该固元膏的工艺流程 |
CN106581292A (zh) * | 2016-10-27 | 2017-04-26 | 武汉龙族药号生物医药科技有限公司 | 龙族膏方及其制备方法 |
CN107467650A (zh) * | 2017-08-21 | 2017-12-15 | 广东橘香斋大健康产业股份有限公司 | 一种红枣阿胶糕及其制备方法 |
-
2019
- 2019-07-19 CN CN201910656409.1A patent/CN110404001A/zh not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1781384A (zh) * | 2004-12-01 | 2006-06-07 | 山东东阿阿胶股份有限公司 | 阿胶膏及其制备方法 |
CN102342497A (zh) * | 2010-07-30 | 2012-02-08 | 欧连 | 固元膏及加工该固元膏的工艺流程 |
CN102335286A (zh) * | 2011-10-28 | 2012-02-01 | 尹留风 | 一种补肾安神食疗的中药组合物 |
CN106581292A (zh) * | 2016-10-27 | 2017-04-26 | 武汉龙族药号生物医药科技有限公司 | 龙族膏方及其制备方法 |
CN107467650A (zh) * | 2017-08-21 | 2017-12-15 | 广东橘香斋大健康产业股份有限公司 | 一种红枣阿胶糕及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103918830B (zh) | 一种暖茶饮料 | |
CN106889233A (zh) | 一种袋泡参苓白术茶及其制备方法 | |
CN103828954A (zh) | 一种减肥茶及其制作方法 | |
CN104232446A (zh) | 一种墨米滋补酒的制备方法 | |
CN106359720A (zh) | 一种清咽利喉和润肺清火的保健茶及其制备方法 | |
CN105454576A (zh) | 茉莉花八宝茶及其制备方法 | |
CN105852084A (zh) | 一种减肥、降血脂功能食品组合物及其制备方法 | |
CN103444928A (zh) | 一种春季养身早茶袋泡茶 | |
CN108157547A (zh) | 一种改善阴虚体质的黄精茶及其制备工艺 | |
CN103444935B (zh) | 一种秋季养身中午茶袋泡茶 | |
CN104893919A (zh) | 一种玉米滋补酒的制备方法 | |
CN108813501A (zh) | 具有清热润肺止咳化痰平喘和调节人体机能的养生蜂蜜膏 | |
CN104312875A (zh) | 一种小米滋补酒的制备方法 | |
KR20160000695A (ko) | Dha 함유 기억력 강화 및 피로회복 증진용 한약재 조성물 수능환 및 그 제조방법 | |
CN107156829A (zh) | 一种适用于肝病患者的全营养配方食品 | |
CN105211441A (zh) | 一种降压降脂的丹参叶保健茶及其制备方法 | |
CN104397282A (zh) | 一种安神补脑的刺五加保健茶及其制备方法 | |
CN101156680B (zh) | 补血抗衰老的食品组合物及其制备方法 | |
CN103461565A (zh) | 一种冬季养身早茶袋泡茶 | |
CN103444950A (zh) | 一种夏季养身早茶袋泡茶 | |
CN110404001A (zh) | 一种具有增强免疫力、改善记忆及抗氧化功能的组合物及其应用 | |
CN103238782A (zh) | 一种杜仲养生挂面及其生产方法 | |
CN103444930B (zh) | 一种秋季养身下午茶袋泡茶 | |
CN103444933B (zh) | 一种夏季养身中午茶袋泡茶 | |
CN104971230A (zh) | 一种增强免疫力的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191105 |
|
WW01 | Invention patent application withdrawn after publication |